Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancer

OBJECTIVE: Few data are available on the optimal treatment options after disease progression from first-line treatment of immune checkpoint inhibitors (ICIs) plus chemotherapy. This study aimed to describe the safety and efficacy of continuing ICIs beyond first progress disease (PD) in non-small cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yixing, Fu, Sha, Zhang, Xuanye, Du, Wei, Luo, Linfeng, Jiang, Yongluo, Zhou, Yixin, Zhao, Yuanyuan, Yang, Yunpeng, Zhao, Hongyun, Fang, Wenfeng, Huang, Yan, Zhang, Li, Hong, Shaodong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258328/
https://www.ncbi.nlm.nih.gov/pubmed/37313402
http://dx.doi.org/10.3389/fimmu.2023.1151385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258328/
https://www.ncbi.nlm.nih.gov/pubmed/37313402
http://dx.doi.org/10.3389/fimmu.2023.1151385

Ejemplares similares